索拉非尼治疗晚期肝癌40例疗效评价

Sorafenib for Treating Advanced Liver Cancer in 40 Cases

目的探讨分子靶向抗肿瘤药索拉非尼治疗晚期肝癌的临床疗效及安全性。方法选择医院2013年1月至6月收治的晚期原发性肝癌患者80例,随机分为对照组和观察组,各40例。对照组患者采用PIAF化疗方案(顺铂、阿霉素、氟尿嘧啶和人重组α-干扰素)化疗方案,观察组在对照组治疗的基础上联合索拉非尼治疗。结果对照组疾病控制率为52.50%,显著低于观察组的67.50%(P<0.05)。观察组6个月以及1年生存率较对照组更高(P<0.05)。两组患者生存质量评分均有改善,观察组生存质量评分明显高于同期对照组(P<0.05)。两组不良反应发生率无明显差异(P>0.05)。结论索拉非尼治疗晚期肝癌,能提高患者的1年生存率,改善肝功能,提高生存质量,其药品不良反应多数程度较轻,且经对症治疗可缓解,值得临床推广。

Objective To investigate the clinical efficacy and safety of molecular targeted antitumor drug sorafenib in the treatment of advanced liver cancer.Methods 80 cases of patients with primary liver cancer from January to June 2013 were randomly divided into the control group and the observation group,40 cases in each group.The control group received PIAF chemotherapy regimens,and on this basis the observation group added with sorafenib.Results The disease control rates of the control group was 52.50%,which was obviously lower than 67.50% of the observation group( P < 0.05); the 6 months and 1 year survival rate of the observation group was higher than that of the control group( P < 0.05) quality of life scores of the two groups after treatment were improved,and observation group was obviously higher than that of the control group( P < 0.05); the incidence of adverse reactions in the two groups had no statistically significant difference( P > 0.05).Conclusion Sorafenib in treating advanced liver cancer can improve the 1 year survival rate of patients,improve liver function,improve the quality of survival,the majority of adverse drug reactions is limited to a lesser degree,and can be alleviated after symptomatic treatment,which is worthy of clinical promotion.